PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Zhao, S.* ; Dorn, J.* ; Napieralski, R.* ; Walch, A.K. ; Diersch, S.* ; Kotzsch, M.* ; Ahmed, N.* ; Hooper, J.* ; Kiechle, M.* ; Schmitt, M.* ; Magdolen, V.*

Plasmin(Ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.

Biol. Chem. 398, 765-773 (2017)
DOI PMC
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
n serous ovarian cancer, the clinical relevance of tumor cell-expressed plasmin(ogen) (PLG) has not yet been evaluated. Due to its proteolytic activity, plasmin supports tumorigenesis, however, angiostatin(-like) fragments, derived from PLG, can also function as potent antitumorigenic factors. In the present study, we assessed PLG protein expression in 103 cases of advanced high-grade serous ovarian cancer (FIGO III/IV) by immunohistochemistry. In 70/103 cases, positive staining of tumor cells was observed. In univariate Cox regression analysis, PLG staining was positively associated with prolonged overall survival (OS) (hazard ratio [HR] = 0.59, P = 0.026) of the patients. In multivariable analysis, PLG, together with residual tumor mass, remained a statistically significant independent prognostic marker (HR = 0.49, P = 0.009). In another small patient cohort (n=29), we assessed mRNA expression levels of PLG by quantitative PCR. Here, elevated PLG mRNA levels were also significantly associated with prolonged OS of patients (Kaplan-Meier analysis; P = 0.001). This finding was validated by in silico analysis of a microarray data set (n = 398) from The Cancer Genome Atlas (Kaplan-Meier analysis; P = 0.031). In summary, these data indicate that elevated PLG expression represents a favorable prognostic biomarker in advanced (FIGO III/IV) high-grade serous ovarian cancer.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
3.273
0.800
10
12
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter immunohistochemistry; PAI-1; plasmin; plasminogen; ovarian cancer; quantitative PCR; uPA; Kallikrein-related Peptidases; Plasminogen-activator; Inhibitor Pai-1; Angiostatin Generation; Thrombostasis Axis; Primary Tumor; Cell-lines; Upa; Expression; Level-of-evidence-1
Sprache englisch
Veröffentlichungsjahr 2017
Prepublished im Jahr 2016
HGF-Berichtsjahr 2016
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Zeitschrift Biological Chemistry
Quellenangaben Band: 398, Heft: 7, Seiten: 765-773 Artikelnummer: , Supplement: ,
Verlag de Gruyter
Verlagsort Berlin
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-500390-001
PubMed ID 27935848
DOI 10.1515/hsz-2016-0282
WOS ID WOS:000403093600005
Scopus ID 85020848002
Erfassungsdatum 2016-12-12
[➜Korrektur melden]